vTv Therapeutics to Present at Peptide Therapeutics Symposium
October 24 2016 - 8:30AM
Business Wire
vTv Therapeutics Inc. (Nasdaq:VTVT), a clinical-stage
biopharmaceutical company engaged in the discovery and development
of new orally administered treatments for Alzheimer’s disease and
diabetes, today announced that the company’s Chief Scientific
Officer Carmen Valcarce, Ph.D., will speak at the 11th Annual
Peptide Therapeutics Symposium at the Salk Institute for Biological
Studies in La Jolla, California. Dr. Valcarce will discuss vTv's
oral GLP-1R program during a presentation titled “Non- Peptide
GLP-1 Receptor Agonists; From Idea to Medicine.” The presentation
is scheduled for 3:00pm on Thursday, October 27.
GLP-1R is a well validated target for the treatment of T2DM,
with multiple marketed injectable GLP-1 analogues/mimetics that
provide glycemic control and weight loss in Type 2 Diabetes
patients. Although several of these peptides targeting GLP-1
receptor have reached blockbuster status, their use has been
limited by two major factors: 1) route of administration being
injections and 2) unfavorable tolerability profile that includes
nausea and vomiting.
Recognizing these drawbacks, scientists at vTv Therapeutics
(vTv) have designed orally bioavailable small molecule
(non-peptide) GLP-1R agonists (TTP054 and TTP273) that have a
favorable tolerability profile being oral agents compared to the
injectable GLP-1 analogues/mimetics. The vTv GLP-1R agonists have
demonstrated efficacy in nonclinical and early stage clinical
studies by improving glycemic control and reducing body weight.
Additionally, vTv’s compounds have shown an impressive tolerability
profile in the clinic.
The on-going Phase 2 LOGRA study is assessing the safety and
efficacy of TTP273 in Type 2 diabetic subjects on stable doses of
metformin. The previous Phase 1b trial of TTP273 showed robust
effects on postprandial and fasting glucose. In this study, all
doses of TTP273 were well tolerated with no serious adverse events
or evidence of significant gastrointestinal side effects. The LOGRA
study is expected to read out at the end of this year.
About vTv Therapeutics
vTv Therapeutics Inc. is a clinical-stage biopharmaceutical
company engaged in the discovery and development of orally
administered small molecule drug candidates to fill significant
unmet medical needs. vTv has a pipeline of clinical drug candidates
led by programs for the treatment of Alzheimer’s disease and Type 2
diabetes as well as treatment of inflammatory disorders and the
prevention of muscle weakness.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20161024005169/en/
vTv
TherapeuticsInvestorsIR@vtvtherapeutics.comorMediaNura
Strong, 336-841-0300 X164PR@vtvtherapeutics.com
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Mar 2024 to Apr 2024
vTv Therapeutics (NASDAQ:VTVT)
Historical Stock Chart
From Apr 2023 to Apr 2024